IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Acquired by Fjarde AP Fonden Fourth Swedish National Pension Fund

Fjarde AP Fonden Fourth Swedish National Pension Fund grew its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 13.5% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 20,992 shares of the company’s stock after purchasing an additional 2,500 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in IDEXX Laboratories were worth $8,679,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently made changes to their positions in IDXX. Wealth Enhancement Advisory Services LLC increased its stake in shares of IDEXX Laboratories by 197.1% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 29,634 shares of the company’s stock worth $14,972,000 after acquiring an additional 19,659 shares during the last quarter. DekaBank Deutsche Girozentrale grew its holdings in shares of IDEXX Laboratories by 1.1% in the third quarter. DekaBank Deutsche Girozentrale now owns 54,792 shares of the company’s stock valued at $27,892,000 after purchasing an additional 572 shares during the period. J.W. Cole Advisors Inc. increased its position in IDEXX Laboratories by 98.3% during the third quarter. J.W. Cole Advisors Inc. now owns 2,642 shares of the company’s stock worth $1,335,000 after purchasing an additional 1,310 shares during the last quarter. Baker Tilly Wealth Management LLC purchased a new position in IDEXX Laboratories during the third quarter worth about $221,000. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in IDEXX Laboratories by 13.8% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 4,511 shares of the company’s stock valued at $2,279,000 after purchasing an additional 547 shares during the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

IDEXX Laboratories Stock Performance

Shares of IDEXX Laboratories stock opened at $463.66 on Tuesday. The stock has a market capitalization of $37.97 billion, a price-to-earnings ratio of 43.45, a price-to-earnings-growth ratio of 3.41 and a beta of 1.37. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95. The business has a 50-day moving average of $432.58 and a 200 day moving average of $452.04. IDEXX Laboratories, Inc. has a 12 month low of $398.50 and a 12 month high of $583.39.

Insider Transactions at IDEXX Laboratories

In related news, EVP George Fennell sold 9,986 shares of the company’s stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the sale, the executive vice president now directly owns 8,176 shares of the company’s stock, valued at $3,781,645.28. This represents a 54.98 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director M Anne Szostak sold 3,000 shares of the firm’s stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the completion of the transaction, the director now directly owns 3,061 shares of the company’s stock, valued at $1,426,242.34. This represents a 49.50 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 13,330 shares of company stock valued at $6,161,276. 2.11% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. Leerink Partnrs upgraded shares of IDEXX Laboratories to a “strong-buy” rating in a report on Monday, December 2nd. Bank of America raised their target price on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a research note on Tuesday, February 4th. Morgan Stanley decreased their price target on IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 29th. Leerink Partners initiated coverage on IDEXX Laboratories in a research report on Monday, December 2nd. They set an “outperform” rating and a $500.00 price objective for the company. Finally, Barclays upped their target price on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a research report on Tuesday, February 4th. Four equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $533.75.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.